AUTL News and Press, Autolus Therapeutics plc From 05/04/23

2023-05-04 07:25:53 ET Autolus Therapeutics press release ( NASDAQ: AUTL ): Q1 GAAP EPS of -$0.23 beats by $0.04 . Cash and cash equivalents and restricted cash at March 31, 2023, totaled $343.4 million, as compared to cash of $382.8 million at December 31, 2022. ...

Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) B-cell Acute Lymphoblastic Leukemia (ALL), on track for next data update at ASCO and EHA, with a Biologics License Application (BLA) submission to the US FDA planned by end of the year Establishing core distri...

LONDON, April 27, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the abstract for the pivotal Phase 2 FELIX study of obecabtagene autoleucel (obe-cel) in...

Cardinal Health to provide core distribution capabilities required for U.S. commercialization of CAR T-cell therapies Innovative Depot Model intended to reduce delivery time by allowing for transit while product release is finalized LONDON, April 27, 2023 (GLOBE NEWSWIRE) -- Autolus The...

LONDON, April 26, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the publication of a paper in Molecular Therapy Nucleic Acids 1 , titled &#...

- Data support utility of AUTO1/22 approach in preventing antigen evasion in pediatric B-ALL - Complete responses observed in patients with CD19 negative disease - No antigen negative relapse seen in responding patients LONDON, April 26, 2023 (GLOBE NEWSWIRE) -- Autolus Th...

LONDON, April 25, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, will host a virtual Capital Markets Day on Thursday, April 27, 2023. Dr Christian Itin, Chief Execu...

LONDON, April 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its first quarter 2023 financial results and operational highlights befo...

- Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR - AUTO1/22 may reduce CD19 negative escape in children with B-ALL, and may have broader applications in improving outcomes in other B-cell malignancies LONDON, April 04, 2023 (GLOBE NEWSWIRE) ...

2023-03-14 07:20:23 ET A clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, Autolus Therapeutics ( NASDAQ: AUTL ) said that Dr. Lucinda Crabtree has provided notice of her resignation as CFO to pursue a new opportu...